Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0I0SY
|
||||
Former ID |
DIB001164
|
||||
Drug Name |
MEDI-542
|
||||
Synonyms |
Ephrin a4-targeting monoclonal antibody (cancer), MedImmune
|
||||
Drug Type |
Antibody
|
||||
Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Terminated | [1] | ||
Company |
Medlmmune LLC
|
||||
Target and Pathway | |||||
Target(s) | Epha4 tyrosine kinase receptor | Target Info | [2] | ||
KEGG Pathway | Axon guidance | ||||
NetPath Pathway | IL2 Signaling Pathway | ||||
Pathway Interaction Database | EphrinA-EPHA pathway | ||||
EPHA forward signaling | |||||
Reactome | EPH-Ephrin signaling | ||||
EPHA-mediated growth cone collapse | |||||
EPH-ephrin mediated repulsion of cells | |||||
WikiPathways | Gene regulatory network modelling somitogenesis | ||||
Spinal Cord Injury | |||||
References | |||||
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021498) | ||||
REF 2 | Product Pipeline Review of MedImmune, LLC in 2012. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.